Treatment with novel topoisomerase inhibitors in Ewing sarcoma models reveals heterogeneity of tumor response.

Survival analysis demonstrated that LMP400-treated mice experienced longer median survival (27 days) compared to irinotecan-treated mice (21 days) although this difference did not reach statistical significance ( p = 0.512) and may not reflect a clinically meaningful difference.

also in 111,027 other papers